About 20% of BC patients are affected by a particular subtype of BC, called triple negative (TNBC), characterized by the lack of ER, PR, and human epidermal growth factor receptor (HER2) expression, and generally accompanied by an aggressive clinical course and poor prognosis [87]. This evidence concerns the gene ERBB2 and breast cancer.